Browsed by
Tag: Law

Creative Law For Artists Series Welcomes Guest Speaker Anika Jackson

Creative Law For Artists Series Welcomes Guest Speaker Anika Jackson

Hosted by DJ Justin Paul.

Creative Law For Artists Series Welcomes Guest Speaker Anika Jackson

This biweekly series is co-hosted by DJ, Producer, and College Professor Justin Paul of Los Angeles, CA; and Drummer, Dr. Who Expert, and Patent Attorney Ira Domnitz of Houston, TX.

Each episode they discuss legal and business issues affecting musicians and/or visual artists and how creatives can protect their work. In this week’s episode, special guest Anika Jackson, founder of AnikaPR in Los Angeles will be sharing great stories and tips about starting, building, and expanding your brand.

At the start of the COVID-19 pandemic, like many musicians, DJ Justin Paul began more heavily using online platforms such as Facebook, Twitch, and others to perform and share music with those who were “safer at home.” Ira Domnitz, Esq. was listening and realized that there was a need for creatives to understand their rights and protect their works whether on or offline. The two gentlemen met, and Creative Law for Artists was founded.

Learn more about them at: justinpaul.com and patent-lawyers.com

The series airs Wednesday, October 14, 2020 at 5 p.m. Los Angeles / 7 p.m. Houston / 8 p.m. New York and Thursday, October 15, 2020 at 1 a.m. London/ 8 a.m. Hong Kong/ 10 a.m. Sydney.

Related Articles
View More
TV Stories

From This Author
TV News Desk

Source Article Read the rest

The 3Q20 IPO Market’s Law Firm Leaderboard

The 3Q20 IPO Market’s Law Firm Leaderboard

The 3Q20 was a record-breaking quarter for IPO activity, with 81 IPOs raising $28.5 billion. Soaring peer multiples and IPO enthusiasm caused activity to increase significantly from the 3Q19, when 39 IPOs raised $10.8 billion. Healthcare was the most active sector, as larger health services providers joined the steady stream of biotechs, followed by tech which saw a surge of activity in September. With every IPO requiring at least two legal firms, one for issuers and one for underwriters (and some hiring as many as seven), the 3Q20 saw 216 legal engagements (414 including SPACs) with 72 law firms.

View our Report on The Most Active Legal Firms of the 3Q20 IPO MarketPDF

To read the entire report, sign up for a free trial of IPO Pro, the platform that gives you all of the IPO information you need, all in one place.

Start a Free Trial of IPO Pro

Read Renaissance Capital’s other quarterly publications:

The article The 3Q20 IPO Market’s Law Firm Leaderboard originally appeared on IPO investment manager Renaissance Capital’s web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital’s research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital’s Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Source Article Read the rest

ROSEN, A TOP RANKED LAW FIRM, Reminds Teva Pharmaceuticals Industries Limited Investors of the …

ROSEN, A TOP RANKED LAW FIRM, Reminds Teva Pharmaceuticals Industries Limited Investors of the …

NEW YORK, Oct. 12, 2020 (GLOBE NEWSWIRE) — Rosen Law Firm, a global investor rights law firm, reminds the purchasers of the securities of Teva Pharmaceuticals Industries Limited (NYSE: TEVA) between October 29, 2015 and August 18, 2020, inclusive (the “Class Period”), of the important November 23, 2020 lead plaintiff deadline in securities class action. The lawsuit seeks to recover damages for Teva investors under the federal securities laws.

To join the Teva class action, go to http://www.rosenlegal.com/cases-register-1956.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding Teva’s business, operational, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Teva had made substantial illegal kickback payments to charitable foundations to cover Medicare co-payment obligations of patients taking Copaxone; (2) accordingly, Teva’s revenues derived from Copaxone were in part the product of unlawful conduct and thus unsustainable; (3) the foregoing misconduct subjected Teva to a foreseeable risk of heightened regulatory scrutiny and enforcement, as well as reputational harm when the truth became known; and (4) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 23, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1956.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law

Read the rest
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioMarin Pharmaceuticals, Inc. of

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioMarin Pharmaceuticals, Inc. of

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on
their Investment in BioMarin Pharmaceuticals, Inc. of Class Action Lawsuit and
Upcoming Deadline – BMRN

NEW YORK, Oct.  08, 2020 (GLOBE  NEWSWIRE) -- Pomerantz  LLP announces that  a
class action lawsuit  has been  filed against  BioMarin Pharmaceuticals,  Inc.
 (“BioMarin” or the “Company”)  (NASDAQ: BMRN) and  certain of its  officers. 
The class  action, filed  in United  States District  Court for  the  Northern
District of California,  and docketed  under 20-cv-06719,  is on  behalf of  a
class consisting  of  all  persons  other than  Defendants  who  purchased  or
otherwise, acquired BioMarin securities between  February 28, 2020 and  August
18, 2020,  both  dates inclusive  (the  “Class Period”),  seeking  to  recover
damages caused by Defendants’ violations of the federal securities laws and to
pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange  Act
of 1934 (the “Exchange  Act”) and Rule  10b-5 promulgated thereunder,  against
the Company and certain of its top officials.

If you are a  shareholder who purchased BioMarin  securities during the  class
period, you have until November 24, 2020,  to ask the Court to appoint you  as
Lead Plaintiff for  the class.  A  copy of  the Complaint can  be obtained  at
www.pomerantzlaw.com.  To discuss this action, contact Robert S. Willoughby at
newaction@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.  7980.
Those who inquire by e-mail are  encouraged to include their mailing  address,
telephone number, and the number of shares purchased. 

         [Click here for information about joining the class action]

BioMarin is a biotechnology company that develops and commercializes therapies
for people  with  serious  and  life-threatening  rare  diseases  and  medical
conditions.  The   Company’s  product   candidates  include,   among   others,
valoctocogene roxaparvovec, an investigational adeno-associated virus  (“AAV”)
gene therapy, which is  in Phase 3 clinical  development for the treatment  of
patients with severe hemophilia A.

Based 
Read the rest
Lifshitz Law Firm, P.C. Announces Investigation of AMAG Pharmaceuticals, Inc., MobileIron, Inc., Monaker Group, Inc., and

Lifshitz Law Firm, P.C. Announces Investigation of AMAG Pharmaceuticals, Inc., MobileIron, Inc., Monaker Group, Inc., and

Lifshitz Law Firm, P.C. Announces Investigation of AMAG Pharmaceuticals, Inc.,
MobileIron, Inc., Monaker Group, Inc., and Seacoast Commerce Banc Holdings

NEW YORK, Oct. 07, 2020 (GLOBE NEWSWIRE) --

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG)

Lifshitz Law  Firm,  P.C.  announces investigation  into  possible  breach  of
fiduciary duties in connection with the sale  of AMAG to Covis Group S.à  r.l.
for $13.75 per share.

If you are a  AMAG investor, and would  like additional information about  our
investigation, please complete the Information Request Form or contact  Joshua
Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

MobileIron, Inc. (NASDAQ GS: MOBL)

Lifshitz Law  Firm,  P.C.  announces investigation  into  possible  breach  of
fiduciary duties in connection with the sale of MOBL to Ivanti, Inc. for $7.05
per share.

If you are a  MOBL investor, and would  like additional information about  our
investigation, please complete the Information Request Form or contact  Joshua
Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

Monaker Group, Inc. (NASDAQ:MKGI)

Lifshitz Law  Firm,  P.C.  announces investigation  into  possible  breach  of
fiduciary duties in  connection with the  sale of MKGI  to Hotplay  Enterprise
Limited.

If you are a  MKGI investor, and would  like additional information about  our
investigation, please complete the Information Request Form or contact  Joshua
Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

Seacoast Commerce Banc Holdings (OTC: SCBH)

Lifshitz Law  Firm,  P.C.  announces investigation  into  possible  breach  of
fiduciary duties in connection with the  sale of SCBH to Enterprise  Financial
Services Corp. for 0.5061 EFS common stock per share.

If you are an SCBH investor,  and would like additional information about  our
investigation, please complete the Information Request Form or contact  Joshua
Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

ATTORNEY ADVERTISING.© 2020 Lifshitz Law  Firm, P.C. The law firm  responsible
for this 
Read the rest